top of page

Retinal Phenotype of Patients with CLRN1-Associated Usher 3A Syndrome in French Light4Deaf Cohort

Apr 29, 2022

Vasily Smirnov, Marco Nassisi, Saddek Mohand-Said, Crystel Bonnet, Anne Aubois, Céline Devisme, Thilissa Dib, Christina Zeitz, Natalie Loundon, Sandrine Marlin, Christine Petit, Bahram Bodaghi, José-Alain Sahel, Isabelle Audo| April 2022 | Investigative Ophthalmology & Visual Science | 63(4) | Pg. 25 | doi: 10.1167/iovs.63.4.25


Abstract

Purpose: Biallelic variants in CLRN1 are responsible for Usher syndrome 3A and non-syndromic rod–cone dystrophy (RCD). Retinal findings in Usher syndrome 3A have not been well defined. We report the detailed phenotypic description of RCD associated with CLRN1 variants in a prospective cohort.


Methods: Patients were clinically investigated at the National Reference Center for rare ocular diseases at the Quinze-Vingts Hospital, Paris, France. Best-corrected visual acuity (BCVA) tests, Goldmann perimetry, full-field electroretinography (ffERG), retinal photography, near-infrared reflectance, short-wavelength and near-infrared autofluorescence, and optical coherence tomography (OCT) were performed for all patients.


Results: Four patients from four unrelated families were recruited. Mean follow-up was 11 years for three patients, and only baseline data were available for one subject. Median BCVA at baseline was 0.2 logMAR (range, 0.3–0). ffERG responses were undetectable in all subjects. The III4e isopter of the Goldmann visual field was constricted to 10°. The retinal phenotype was consistent in all patients: small whitish granular atrophic areas were organized in a network pattern around the macula and in the midperiphery. OCT showed intraretinal microcysts in all patients. Upon follow-up, all patients experienced a progressive BCVA loss and further visual field constriction. Four distinct pathogenic variants were identified in our patients: two missense (c.144T>G, p.(Asn48Lys) and c.368C>A, p.(Ala123Asp)) and two frameshift variants (c.176del, p.(Gly59Valfs*13) and c.230dup, p.(Ala78Serfs*52)).


Conclusions: RCD in Usher 3A syndrome has some distinctive features. It is a severe photoreceptor dystrophy with whitish granular posterior pole appearance and cystic maculopathy.


 

References

  1. Boughman JA, Vernon M, Shaver KA. Usher syndrome: definition and estimate of prevalence from two high-risk populations. J Chronic Dis. 1983; 36(8): 595–603.

  2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006; 368(9549): 1795–1809.

  3. Keats BJ, Corey DP. The usher syndromes. Am J Med Genet. 1999; 89(3): 158–166.

  4. Kimberling WJ, Hildebrand MS, Shearer AE, et al. Frequency of Usher syndrome in two pediatric populations: implications for genetic screening of deaf and hard of hearing children. Genet Med. 2010; 12(8): 512–516.

  5. Mathur PD, Yang J. Usher syndrome and non-syndromic deafness: functions of different whirlin isoforms in the cochlea, vestibular organs, and retina. Hear Res. 2019; 375: 14–24.

  6. Heissler SM, Manstein DJ. Functional characterization of the human myosin-7a motor domain. Cell Mol Life Sci. 2012; 69(2): 299–311.

  7. Weil D, Blanchard S, Kaplan J, et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature. 1995; 374(6517): 60–61.

  8. Bonnet C, El-Amraoui A. Usher syndrome (sensorineural deafness and retinitis pigmentosa): pathogenesis, molecular diagnosis and therapeutic approaches. Curr Opin Neurol. 2012; 25(1): 42–49.

  9. Bhattacharya G, Kalluri R, Orten DJ, Kimberling WJ, Cosgrove D. A domain-specific usherin/collagen IV interaction may be required for stable integration into the basement membrane superstructure. J Cell Sci. 2004; 117(2): 233–242.

  10. Eudy JD, Weston MD, Yao S, et al. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science. 1998; 280(5370): 1753–1757.

  11. Seyedahmadi BJ, Rivolta C, Keene JA, Berson EL, Dryja TP. Comprehensive screening of the USH2A gene in Usher syndrome type II and non-syndromic recessive retinitis pigmentosa. Exp Eye Res. 2004; 79(2): 167–173.

  12. Ávila-Fernández A, Cantalapiedra D, Aller E, et al. Mutation analysis of 272 Spanish families affected by autosomal recessive retinitis pigmentosa using a genotyping microarray. Mol Vis. 2010; 16: 2550–2558.

  13. McGee TL, Seyedahmadi BJ, Sweeney MO, Dryja TP, Berson EL. Novel mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis pigmentosa. J Med Genet. 2010; 47(7): 499–506.

  14. Nuutila A. Dystrophia retinae pigmentosa–dysacusis syndrome (DRD): a study of the Usher- or Hallgren syndrome. J Genet Hum. 1970; 18(1): 57–88.

  15. Gorlin RJ, Tilsner TJ, Feinstein S, Duvall AJ. Usher's syndrome type III. Arch Otolaryngol Chic Ill 1960. 1979; 105(6): 353–354.

  16. Sadeghi M, Cohn ES, Kimberling WJ, Tranebjaerg L, Möller C. Audiological and vestibular features in affected subjects with USH3: a genotype/phenotype correlation. Int J Audiol. 2005; 44(5): 307–316.

  17. Adato A, Vreugde S, Joensuu T, et al. USH3A transcripts encode clarin-1, a four-transmembrane-domain protein with a possible role in sensory synapses. Eur J Hum Genet. 2002; 10(6): 339–350.

  18. Abbott JA, Meyer-Schuman R, Lupo V, et al. Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat. 2018; 39(3): 415–432.

  19. Khan MI, Kersten FFJ, Azam M, et al. CLRN1 mutations cause nonsyndromic retinitis pigmentosa. Ophthalmology. 2011 Jul 1; 118(7): 1444–1448.

  20. Puffenberger EG, Jinks RN, Sougnez C, et al. Genetic mapping and exome sequencing identify variants associated with five novel diseases. PLoS One. 2012; 7(1): e28936.

  21. Vester A, Velez-Ruiz G, McLaughlin HM, et al. A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum Mutat. 2013; 34(1): 191–199.

  22. Safka Brozkova D, Deconinck T, Griffin LB, et al. Loss of function mutations in HARS cause a spectrum of inherited peripheral neuropathies. Brain J Neurol. 2015; 138(Pt 8): 2161–2172.

  23. Galatolo D, Kuo ME, Mullen P, et al. Bi-allelic mutations in HARS1 severely impair histidyl-tRNA synthetase expression and enzymatic activity causing a novel multisystem ataxic syndrome. Hum Mutat. 2020; 41(7): 1232–1237.

  24. Bonnet C, Riahi Z, Chantot-Bastaraud S, et al. An innovative strategy for the molecular diagnosis of Usher syndrome identifies causal biallelic mutations in 93% of European patients. Eur J Hum Genet. 2016; 24(12): 1730–1738.

  25. Pakarinen L, Tuppurainen K, Laippala P, Mäntyjärvi M, Puhakka H. The ophthalmological course of Usher syndrome type III. Int Ophthalmol. 1995; 19(5): 307–311.

  26. Khalaileh A, Abu-Diab A, Ben-Yosef T, et al. The genetics of Usher syndrome in the Israeli and Palestinian populations. Invest Ophthalmol Vis Sci. 2018; 59(2): 1095–1104.

  27. Fields RR, Zhou G, Huang D, et al. Usher syndrome type III: revised genomic structure of the USH3 gene and identification of novel mutations. Am J Hum Genet. 2002; 71(3): 607–617.

  28. Ness SL, Ben-Yosef T, Bar-Lev A, et al. Genetic homogeneity and phenotypic variability among Ashkenazi Jews with Usher syndrome type III. J Med Genet. 2003; 40(10): 767–772.

  29. Herrera W, Aleman TS, Cideciyan AV, et al. Retinal disease in Usher syndrome III caused by mutations in the clarin-1 gene. Invest Ophthalmol Vis Sci. 2008; 49(6): 2651.

  30. Ratnam K, Västinsalo H, Roorda A, Sankila E-MK, Duncan JL. Cone structure in patients with usher syndrome type III and mutations in the Clarin 1 gene. JAMA Ophthalmol. 2013; 131(1): 67–74.

  31. Audo I, Friedrich A, Mohand-Saïd S, Lancelot M-E, Antonio A, Moskova-Doumanova V, Poch O, Bhattacharya S, Sahel J-A, Zeitz C. An unusual retinal phenotype associated with a novel mutation in RHO. Arch Ophthalmol. 2010; 128(8): 1036–1045.

  32. Joensuu T, Hämäläinen R, Yuan B, et al. Mutations in a novel gene with transmembrane domains underlie Usher syndrome type 3. Am J Hum Genet. 2001; 69(4): 673–684.

  33. Ebermann I, Lopez I, Bitner-Glindzicz M, Brown C, Koenekoop RK, Bolz HJ. Deafblindness in French Canadians from Quebec: a predominant founder mutation in the USH1C gene provides the first genetic link with the Acadian population. Genome Biol. 2007; 8(4): R47.

  34. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405–424.

  35. Pakarinen L, Karjalainen S, Simola KOJ, Laippala P, Kaitalo H. Usher's syndrome type 3 in Finland. Laryngoscope. 1995; 105(6): 613–617.

  36. Plantinga RF, Pennings RJE, Huygen PLM, et al. Visual impairment in Finnish Usher syndrome type III. Acta Ophthalmol Scand. 2006; 84(1): 36–41.

  37. Duncker T, Tabacaru MR, Lee W, Tsang SH, Sparrow JR, Greenstein VC. Comparison of near-infrared and short-wavelength autofluorescence in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013; 54(1): 585–591.

  38. Nassisi M, Lavia C, Mohand-Said S, et al. Near-infrared fundus autofluorescence alterations correlate with swept-source optical coherence tomography angiography findings in patients with retinitis pigmentosa. Sci Rep. 2021; 11(1): 3180.

  39. Ebermann I, Wilke R, Lauhoff T, Lübben D, Zrenner E, Bolz HJ. Two truncating USH3A mutations, including one novel, in a German family with Usher syndrome. Mol Vis. 2007; 13: 1539–1547.

  40. Västinsalo H, Jalkanen R, Dinculescu A, et al. Alternative splice variants of the USH3A gene Clarin 1 (CLRN1). Eur J Hum Genet. 2011; 19(1): 30–35.

  41. Zallocchi M, Meehan DT, Delimont D, et al. Localization and expression of clarin-1, the Clrn1 gene product, in auditory hair cells and photoreceptors. Hear Res. 2009; 255(1–2): 109–120.

  42. Xu L, Bolch SN, Santiago CP, et al. Clarin-1 expression in adult mouse and human retina highlights a role of Müller glia in Usher syndrome. J Pathol. 2020; 250(2): 195–204.

  43. Geller SF, Guerin KI, Visel M, et al. CLRN1 is nonessential in the mouse retina but is required for cochlear hair cell development. PLoS Genet; 5(8): e1000607.

  44. Sahly I, Dufour E, Schietroma C, et al. Localization of Usher 1 proteins to the photoreceptor calyceal processes, which are absent from mice. J Cell Biol. 2012; 199(2): 381–399.

  45. Dinculescu A, Stupay RM, Deng W-T, et al. AAV-mediated clarin-1 expression in the mouse retina: implications for USH3A gene therapy. PLoS One. 2016; 11(2): e0148874.

  46. Geng R, Melki S, Chen DH-C, et al. The mechanosensory structure of the hair cell requires clarin-1, a protein encoded by Usher syndrome III causative gene. J Neurosci. 2012; 32(28): 9485–9498.

  47. Tian G, Zhou Y, Hajkova D, et al. Clarin-1, encoded by the Usher syndrome III causative gene, forms a membranous microdomain: possible role of clarin-1 in organizing the actin cytoskeleton. J Biol Chem. 2009; 284(28): 18980–18993.

  48. Geng R, Omar A, Gopal SR, et al. Modeling and preventing progressive hearing loss in Usher syndrome III. Sci Rep. 2017; 7(1): 13480.

  49. Geng R, Geller SF, Hayashi T, et al. Usher syndrome IIIA gene clarin-1 is essential for hair cell function and associated neural activation. Hum Mol Genet. 2009; 18(15): 2748–2760.

Comments

Commenting has been turned off.
bottom of page